An Open-label Phase Ib Prospective Clinical Trial to Investigate Safety, Tolerability and Maximum Tolerated Dose for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
Latest Information Update: 06 Dec 2023
At a glance
- Drugs Endovion (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms PANTAX-Ib
- Sponsors Scandion Oncology
Most Recent Events
- 24 Oct 2023 Results assessing primary objective to determine safety and Maximum Tolerated Dose by evaluation of Dose-Limiting Toxicities related to SCO-101 during the first treatment cycle presented at the 48th European Society for Medical Oncology Congress.
- 28 Dec 2021 Planned primary completion date changed from 30 Sep 2021 to 30 Mar 2022.
- 26 Nov 2020 Status changed from not yet recruiting to recruiting.